Juvenile idiopathic arthritis
Therapeutic area
Rheumatology
Rare disease
Yes
- Definition
- Juvenile idiopathic arthritis (JIA) is the term used to describe a group of inflammatory articular disorders of unknown cause that begin before the age of 16 and last over 6 weeks. The term juvenile idiopathic arthritis was chosen to signify the absence of any known mechanism underlying the disorder and to highlight the necessity of excluding other types of arthritis occurring in well defined diseases (in particular arthritis occurring in association with infectious, inflammatory and haematooncologic diseases).
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Juvenile idiopathic arthritis
- Therapeutic area
- Rheumatology
- juvenile idiopathic arthritis
- JIA
- Juvenile Idiopathic Arthritis (JIA)
- Juvenile Idiopathic Arthritis, Oligoarthritis
- juvenile rheumatoid arthritis
- Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
- Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
- Refractory Juvenile Idiopathic Arthritis (Despite 2 DMARDs Still Active)
- rheumatoid arthritis, systemic juvenile, susceptibility to
- acute juvenile rheumatoid arthritis
- monarticular juvenile rheumatoid arthritis
- pauciarticular juvenile arthritis
- pauciarticular onset juvenile chronic arthritis
- systemic juvenile rheumatoid arthritis
- Disease mechanisms
- Inflammatory
Sources for recorded values
- All therapeutic areas
- Rheumatology
Sources for recorded values
- Severity
- Severe
- MONDO ID
- MONDO:0011429
- Parent condition
- MONDO:0005554
Related records
Broader conditions (15)
- Arthritic joint disease
- Arthropathy
- Bone disorder
- Bone inflammation disease
- Connective tissue disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Human disease
- Idiopathic disease
- Inflammatory disease
- Musculoskeletal system disorder
- Rheumatic disorder
- Skeletal system disorder
Narrower conditions (12)
- Enthesitis-related juvenile idiopathic arthritis
- Oligoarticular juvenile idiopathic arthritis
- Oligoarticular juvenile idiopathic arthritis with anti-nuclear antibodies
- Oligoarticular juvenile idiopathic arthritis without anti-nuclear antibodies
- Polyarticular juvenile idiopathic arthritis
- Psoriasis-related juvenile idiopathic arthritis
- Rheumatoid factor-negative juvenile idiopathic arthritis
- Rheumatoid factor-negative juvenile idiopathic arthritis with anti-nuclear antibodies
- Rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies
- Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis
- Systemic-onset juvenile idiopathic arthritis
- Unspecified juvenile idiopathic arthritis
Trials (358)
- "Medikidz Explain JIA Comic Book- Hebrew"
- (1,3)-Béta-D-Glucan Levels at Diagnosis of Juvenile Idiopathic Arthritis and Its Correlation With Activity's Disease : a Cohort Sudy
- 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy
- A Clinical Study With Adalimumab Biosimilar
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study
- A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
- A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)
- A Peer E-mentoring Intervention to Improve Employment
- A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
- A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
- A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
- A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
- A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA
- A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
- A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
- A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
- A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
- A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
- A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
Approved drugs (27)
- Abatacept
- Adalimumab
- Canakinumab
- Celecoxib
- Cortisone acetate
- Dexamethasone
- Dexamethasone sodium phosphate
- Etanercept
- Etodolac
- Hydrocortisone
- Ibuprofen
- Ibuprofen arginine
- Ibuprofen sodium
- Ixekizumab
- Meclofenamate sodium
- Meloxicam
- Methotrexate
- Methotrexate sodium
- Methylprednisolone
- Naproxen
Drugs in development (32)
- Anakinra Phase 2
- Baricitinib Phase 3
- Bimekizumab Phase 3
- Calcium Phase 3
- Calcium carbonate Phase 2
- Certolizumab pegol Phase 3
- Cholecalciferol Phase 3
- Daclizumab Phase 2
- Elasomeran Phase 2
- Ergocalciferol Phase 2
- Esomeprazole Phase 1
- Filgotinib Phase 1
- Filgotinib hydrochloride Phase 3
- Givinostat Phase 2
- Golimumab Phase 3
- Guselkumab Phase 3
- Hydroxychloroquine Phase 3
- Infliximab Phase 3
- Influenza virus vaccine Early phase 1
- Olokizumab Phase 2
Other linked drugs (6)
- Aldesleukin
- Antilymphocyte immunoglobulin (horse)
- Cyclophosphamide
- Cyclosporine
- Filgrastim
- Gamolenic acid